Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for multiple sclerosis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Correlation between CTLA-4 gene rs221775A>G single nucleotide polymorphism and multiplesclerosis susceptibility. A meta-analysis. The aim of this meta-analysis was to undertake a meta-analysis to evaluate the correlation between cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) gene rs221775 A>G single nucleotide polymorphism and the susceptibility of multiplesclerosis (MS) susceptibility.Published manuscripts about CTLA-4 gene rs221775A>G single nucleotide polymorphism and multiple (...) sclerosis susceptibility were searched in the computerized bibliographic searches of Pubmed Embase and China National Knowledge Infrastructure (CNKI). Potential studies were screened and data for 5025 MS patients and 4706 controls from 20 publications were included. The association between CTLA-4 gene rs221775A>G single nucleotide polymorphism and multiplesclerosis susceptibility were demonstrated by odds ratio (OR) and 95% confidence interval (95%CI).The pooled results showed no significant
Stress and multiplesclerosis: A systematic review considering potential moderating and mediating factors and methods of assessing stress. Research about the effects of stress on multiplesclerosis has yielded contradictory results. This study aims to systematically review the evidence focusing on two possible causes: the role of stress assessment and potential moderating and mediating factors. The Web of Knowledge (MEDLINE and Web of Science), Scopus, and PsycINFO databases were searched (...) for relevant articles published from 1900 through December 2014 using the terms "stress*" AND "multiplesclerosis." Twenty-three articles were included. Studies focused on the effect of stress on multiplesclerosis onset (n = 9) were mostly retrospective, and semi-structured interviews and scales yielded the most consistent associations. Studies focused on multiplesclerosis progression (n = 14) were mostly prospective, and self-reported diaries yielded the most consistent results. The most important
Living near major roads and the incidence of dementia, Parkinson's disease, and multiplesclerosis: a population-based cohort study. Emerging evidence suggests that living near major roads might adversely affect cognition. However, little is known about its relationship with the incidence of dementia, Parkinson's disease, and multiplesclerosis. We aimed to investigate the association between residential proximity to major roadways and the incidence of these three neurological diseases (...) in Ontario, Canada.In this population-based cohort study, we assembled two population-based cohorts including all adults aged 20-50 years (about 4·4 million; multiplesclerosis cohort) and all adults aged 55-85 years (about 2·2 million; dementia or Parkinson's disease cohort) who resided in Ontario, Canada on April 1, 2001. Eligible patients were free of these neurological diseases, Ontario residents for 5 years or longer, and Canadian-born. We ascertained the individual's proximity to major roadways
Ocrevus - ocrelizumab - Primary progressive multiplesclerosis ocrelizumab | CADTH.ca Find the information you need ocrelizumab ocrelizumab Last Updated: May 9, 2018 Result type: Reports Project Number: SR0542-000 Product Line: Generic Name: ocrelizumab Brand Name: Ocrevus Manufacturer: Hoffman-La Roche Limited Indications: Primary progressive multiplesclerosis Submission Type: New Indication Project Status: Complete Biosimilar: No Date Recommendation Issued: April 26, 2018 Recommendation Type (...) to applicant and drug plans April 05, 2018 Embargo period ended and validation of redacted CDR review report(s) received April 19, 2018 CDEC Final Recommendation issued to applicant and drug plans April 26, 2018 CDEC Final Recommendation posted April 30, 2018 Final CDR review report(s) and patient input posted May 08, 2018 Tags multiplesclerosis, multiplesclerosis, chronic progressive, multiplesclerosis, relapsing-remitting, Ocrevus; ocrelizumab; PPMS; primary progressive multiplesclerosis Files Follow
Ocrelizumab (Ocrevus Genentech Inc.) for primary progressive and relapsing-remitting multiplesclerosis Ocrelizumab (Ocrevus; Genentech Inc.) for primary progressive and relapsing-remitting multiplesclerosis Ocrelizumab (Ocrevus; Genentech Inc.) for primary progressive and relapsing-remitting multiplesclerosis HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation HAYES, Inc. Ocrelizumab (Ocrevus; Genentech Inc.) for primary progressive and relapsing-remitting multiplesclerosis. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2017 Authors' conclusions Multiplesclerosis (MS) is an autoimmune disorder that impacts the spinal cord and brain. MS presents in various forms, including relapsing-remitting MS (RRMS) or primary progressive MS (PPMS). Technology Description: Ocrelizumab (Ocrevus) is a humanized monoclonal antibody therapy
Fingolimod (Gilenya) - highly active relapsing remitting multiplesclerosis Final Appraisal Recommendation Advice No: 3516 – December 2016 Fingolimod (Gilenya ® ) 0.5 mg hard capsules Submission by Novartis Pharmaceuticals UK Ltd Additional note(s): • Please refer to the Summary of Product Characteristics for the full licensed indication. In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3135), which (...) in full and cited as: All Wales Medicines Strategy Group Final Appraisal Recommendation – 3516: Fingolimod (Gilenya ® ) 0.5 mg hard capsules December 2016 Recommendation of AWMSG Fingolimod (Gilenya ® ) is recommended as an option for use within NHS Wales for use as a single disease modifying therapy in highly active relapsing remitting multiplesclerosis for the following adult patient group: - patients with rapidly evolving severe relapsing remitting multiplesclerosis defined by 2 or more disabling
29 Year Old Man with MultipleSclerosis and Schizophrenia: A Case Report Multiplesclerosis (MS) is the most common debilitating neurological disease that affects adults, whether young adults or middle-aged. Although, most attention is toward the neurological signs of the disease, the neuropsychiatric signs are not uncommon. This case report presents a 29 year old male with a record of obsessive-compulsive disorder (OCD) without psychotic disorder, which coincides with the diagnosis MS, has
Ocrelizumab versus Interferon Beta-1a in Relapsing MultipleSclerosis. B cells influence the pathogenesis of multiplesclerosis. Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B cells.In two identical phase 3 trials, we randomly assigned 821 and 835 patients with relapsing multiplesclerosis to receive intravenous ocrelizumab at a dose of 600 mg every 24 weeks or subcutaneous interferon beta-1a at a dose of 44 μg three times weekly for 96 weeks. The primary end (...) to 0.81; P<0.001), as was the percentage of patients with disability progression confirmed at 24 weeks (6.9% vs. 10.5%; hazard ratio, 0.60; 95% CI, 0.43 to 0.84; P=0.003). The mean number of gadolinium-enhancing lesions per T1-weighted magnetic resonance scan was 0.02 with ocrelizumab versus 0.29 with interferon beta-1a in trial 1 (94% lower number of lesions with ocrelizumab, P<0.001) and 0.02 versus 0.42 in trial 2 (95% lower number of lesions, P<0.001). The change in the MultipleSclerosis
Ocrelizumab versus Placebo in Primary Progressive MultipleSclerosis. An evolving understanding of the immunopathogenesis of multiplesclerosis suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a humanized monoclonal antibody that selectively depletes CD20-expressing B cells, in the primary progressive form of the disease.In this phase 3 trial, we randomly assigned 732 patients with primary progressive multiplesclerosis in a 2:1 ratio to receive intravenous (...) of serious adverse events and serious infections.Among patients with primary progressive multiplesclerosis, ocrelizumab was associated with lower rates of clinical and MRI progression than placebo. Extended observation is required to determine the long-term safety and efficacy of ocrelizumab. (Funded by F. Hoffmann-La Roche; ORATORIO ClinicalTrials.gov number, NCT01194570 .).
Effectiveness and user experience of web-based interventions for increasing physical activity in people with multiplesclerosis: a comprehensive systematic review protocol. The overall aim of this comprehensive systematic review is to explore the use of web-based interventions for increasing physical activity levels in people with a diagnosis of multiplesclerosis (MS).The quantitative objectives are to identify:The qualitative objectives are to.
Modelling disease progression in relapsing-remitting onset multiplesclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort Modelling disease progression in relapsing-remitting onset multiplesclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort Modelling disease progression in relapsing-remitting onset multiplesclerosis using multilevel models applied to longitudinal (...) multiplesclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort. Health Technology Assessment 2016; 20(81) Authors' objectives The ability to better predict disease progression represents a major unmet need in multiplesclerosis (MS), and would help to inform therapeutic and management choices. This study aims to develop multilevel models using longitudinal data on disease progression in patients with relapsing–remitting MS (RRMS
Interferons-beta versus glatiramer acetate for relapsing-remitting multiplesclerosis. Interferons-beta (IFNs-beta) and glatiramer acetate (GA) were the first two disease-modifying therapies (DMTs) approved 20 years ago for the treatment of multiplesclerosis (MS). DMTs' prescription rates as first or switching therapies and their costs have both increased substantially over the past decade. As more DMTs become available, the choice of a specific DMT should reflect the risk/benefit profile (...) acetate for relapsing-remitting multiplesclerosis' (first published in the Cochrane Library 2014, Issue 7).To assess whether IFNs-beta and GA differ in terms of safety and efficacy in the treatment of people with relapsing-remitting (RR) MS.We searched the Trials Register of the Cochrane MultipleSclerosis and Rare Diseases of the CNS Group (08 August 2016) and the reference lists of retrieved articles. We contacted authors and pharmaceutical companies.Randomised controlled trials (RCTs) comparing
Diagnosis of multiplesclerosis: progress and challenges. The diagnosis of multiplesclerosis is based on neurological symptoms and signs, alongside evidence of dissemination of CNS lesions in space and time. MRI is often sufficient to confirm the diagnosis when characteristic lesions accompany a typical clinical syndrome, but in some patients, further supportive information is obtained from cerebrospinal fluid examination and neurophysiological testing. Differentiation is important from other (...) diseases in which demyelination is a feature (eg, neuromyelitis optica spectrum disorder and acute disseminated encephalomyelitis) and from non-demyelinating disorders such as chronic small vessel disease and other inflammatory, granulomatous, infective, metabolic, and genetic causes that can mimic multiplesclerosis. Advances in MRI and serological and genetic testing have greatly increased accuracy in distinguishing multiplesclerosis from these disorders, but misdiagnosis can occur. In this Series